ZA200604578B - Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters - Google Patents
Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters Download PDFInfo
- Publication number
- ZA200604578B ZA200604578B ZA200604578A ZA200604578A ZA200604578B ZA 200604578 B ZA200604578 B ZA 200604578B ZA 200604578 A ZA200604578 A ZA 200604578A ZA 200604578 A ZA200604578 A ZA 200604578A ZA 200604578 B ZA200604578 B ZA 200604578B
- Authority
- ZA
- South Africa
- Prior art keywords
- optionally substituted
- independently
- nitrogen
- sulfur
- optionally
- Prior art date
Links
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 title claims description 33
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 title claims description 33
- 150000002916 oxazoles Chemical class 0.000 title 1
- 150000003557 thiazoles Chemical class 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 claims description 125
- 229910052757 nitrogen Inorganic materials 0.000 claims description 110
- 229910052717 sulfur Chemical group 0.000 claims description 109
- 150000001875 compounds Chemical class 0.000 claims description 102
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 100
- 229920006395 saturated elastomer Polymers 0.000 claims description 97
- 125000005842 heteroatom Chemical group 0.000 claims description 93
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 90
- 239000011593 sulfur Chemical group 0.000 claims description 90
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 89
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 88
- 239000001301 oxygen Chemical group 0.000 claims description 88
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 84
- 229910052736 halogen Inorganic materials 0.000 claims description 69
- 150000002367 halogens Chemical class 0.000 claims description 69
- 229910052739 hydrogen Inorganic materials 0.000 claims description 67
- 239000001257 hydrogen Substances 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 63
- 125000001118 alkylidene group Chemical group 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 49
- 125000002950 monocyclic group Chemical group 0.000 claims description 48
- 125000001931 aliphatic group Chemical group 0.000 claims description 46
- 125000004429 atom Chemical group 0.000 claims description 33
- 150000002431 hydrogen Chemical class 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000002619 bicyclic group Chemical group 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 206010012735 Diarrhoea Diseases 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 12
- 201000010064 diabetes insipidus Diseases 0.000 claims description 12
- -1 4,5-dihydro-2-oxazolyl Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 108091006146 Channels Proteins 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 7
- 206010014561 Emphysema Diseases 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 102000011045 Chloride Channels Human genes 0.000 claims description 5
- 108010062745 Chloride Channels Proteins 0.000 claims description 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 201000009881 secretory diarrhea Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 102100032187 Androgen receptor Human genes 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 3
- 206010062264 Congenital hyperthyroidism Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 206010013883 Dwarfism Diseases 0.000 claims description 3
- 208000024720 Fabry Disease Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 3
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 3
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims description 3
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 3
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims description 3
- 208000000038 Hypoparathyroidism Diseases 0.000 claims description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 3
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000025237 Polyendocrinopathy Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 201000005660 Protein C Deficiency Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 3
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 108010040003 polyglutamine Proteins 0.000 claims description 3
- 229920000155 polyglutamine Polymers 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims 18
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 claims 10
- 108091006515 Anion channels Proteins 0.000 claims 6
- 102000037829 Anion channels Human genes 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000003003 spiro group Chemical group 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical class O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 101000894570 Helianthus annuus Alpha-copaene synthase Proteins 0.000 claims 1
- 241001553014 Myrsine salicina Species 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 229940037201 oris Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- LSEKLPKUWRDLKY-UHFFFAOYSA-N protoleucomelone Chemical compound C1=CC(OC(=O)C)=CC=C1C1=C(OC(C)=O)C(OC(C)=O)=C(C=2C(=CC(OC(C)=O)=C(OC(C)=O)C=2)O2)C2=C1OC(C)=O LSEKLPKUWRDLKY-UHFFFAOYSA-N 0.000 claims 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 31
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 22
- 230000032258 transport Effects 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 230000002950 deficient Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 230000007257 malfunction Effects 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- 101150029409 CFTR gene Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 208000028782 Hereditary disease Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000008955 Mucolipidoses Diseases 0.000 description 2
- 206010072928 Mucolipidosis type II Diseases 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 206010039231 Rotaviral infections Diseases 0.000 description 2
- 102000003673 Symporters Human genes 0.000 description 2
- 108090000088 Symporters Proteins 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 230000000420 mucociliary effect Effects 0.000 description 2
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000020978 protein processing Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XUSNPFGLKGCWGN-UHFFFAOYSA-N 3-[4-(3-aminopropyl)piperazin-1-yl]propan-1-amine Chemical compound NCCCN1CCN(CCCN)CC1 XUSNPFGLKGCWGN-UHFFFAOYSA-N 0.000 description 1
- 102000041092 ABC transporter family Human genes 0.000 description 1
- 108091060858 ABC transporter family Proteins 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000209761 Avena Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000014842 Multidrug resistance proteins Human genes 0.000 description 1
- 108050005144 Multidrug resistance proteins Proteins 0.000 description 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100035917 Peripheral myelin protein 22 Human genes 0.000 description 1
- 101710199257 Peripheral myelin protein 22 Proteins 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 210000005058 airway cell Anatomy 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 108010091624 preproparathormone Proteins 0.000 description 1
- 208000007153 proteostasis deficiencies Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000036575 thermal burns Effects 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52035503P | 2003-11-14 | 2003-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200604578B true ZA200604578B (en) | 2008-05-28 |
Family
ID=34619457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200604578A ZA200604578B (en) | 2003-11-14 | 2004-11-15 | Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7407976B2 (fr) |
| EP (2) | EP1682127B1 (fr) |
| JP (1) | JP4869072B2 (fr) |
| KR (1) | KR20060121185A (fr) |
| CN (2) | CN1925854A (fr) |
| AT (1) | ATE437640T1 (fr) |
| AU (1) | AU2004290581B2 (fr) |
| CA (1) | CA2545719A1 (fr) |
| DE (1) | DE602004022319D1 (fr) |
| ES (1) | ES2328824T3 (fr) |
| HK (1) | HK1092353A1 (fr) |
| MX (1) | MXPA06005343A (fr) |
| NO (1) | NO20062773L (fr) |
| NZ (1) | NZ547220A (fr) |
| RU (1) | RU2006120549A (fr) |
| WO (1) | WO2005049018A1 (fr) |
| ZA (1) | ZA200604578B (fr) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| MXPA05008309A (es) * | 2003-02-10 | 2005-09-20 | Amgen Inc | Ligandos de receptor vaniloide y su uso en tratamientos. |
| MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| ES2328824T3 (es) * | 2003-11-14 | 2009-11-18 | Vertex Pharmaceuticals Incorporated | Tiazoles y oxazoles utiles como moduladores de transportadores de tipo casete de union a atp. |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| ES2656017T3 (es) | 2004-06-24 | 2018-02-22 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| KR20080053297A (ko) | 2005-08-11 | 2008-06-12 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유종 트랜스막 전도도 조정자의 조절자 |
| EP1945632B1 (fr) | 2005-11-08 | 2013-09-18 | Vertex Pharmaceuticals Incorporated | Modulateurs hétérocycliques de transporteurs à cassette liant l' atp |
| DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
| EP2016065B1 (fr) * | 2005-12-28 | 2012-09-19 | Vertex Pharmaceuticals Incorporated | Dérivés de la 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide et composés similaires en tant que modulateurs des transporteurs de cassettes de liaison de l'atp pour le traitement de la fibrose cystique |
| US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CA2636826C (fr) * | 2006-01-18 | 2011-11-29 | F.Hoffmann-La Roche Ag | Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1 |
| MX2008012064A (es) * | 2006-03-23 | 2008-12-17 | Amgen Inc | Compuestos de amida 1-fenilsulfonil-diaza-heterociclica y sus usos como moduladores de hidroxiesteroide deshidrogenadas. |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| CA2869945C (fr) | 2006-04-07 | 2018-01-23 | Vertex Pharmaceuticals Incorporated | Modulateurs des transporteurs de cassettes de liaison de l'atp |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| EP2009005A4 (fr) | 2006-04-19 | 2010-06-02 | Astellas Pharma Inc | Dérivé d'azolecarboxamide |
| US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| WO2008073461A2 (fr) * | 2006-12-11 | 2008-06-19 | Wyeth | Modulateurs de canaux ioniques |
| GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| JP2010523579A (ja) * | 2007-04-02 | 2010-07-15 | インスティテュート フォア ワンワールド ヘルス | Ｃｆｔｒ阻害剤化合物およびそれらの使用 |
| CA2687715A1 (fr) * | 2007-05-09 | 2008-11-20 | Traffick Therapeutics Inc. | Dosage de criblage pour identifier des correcteurs de defauts de trafic des proteines |
| EP2789606B1 (fr) | 2007-05-09 | 2017-11-15 | Vertex Pharmaceuticals Incorporated | Modulateurs de CFTR |
| SI2178865T1 (sl) | 2007-07-19 | 2015-11-30 | Lundbeck, H., A/S | 5-členski heterociklični amidi in sorodne spojine |
| CA2696298C (fr) | 2007-08-24 | 2016-09-06 | Vertex Pharmaceuticals Incorporated | Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique |
| PL2206707T3 (pl) | 2007-10-24 | 2015-01-30 | Astellas Pharma Inc | Związek azolokarboksamidowy lub jego sól |
| EP3012250B1 (fr) | 2007-11-16 | 2017-11-08 | Vertex Pharmaceuticals Incorporated | Modulateurs d'isoquinoleine de transporteurs de cassette de liaison a l'atp |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| NZ612635A (en) | 2007-12-07 | 2015-06-26 | Vertex Pharma | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| JP2011506331A (ja) * | 2007-12-07 | 2011-03-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の処方物 |
| EP3683218B1 (fr) | 2007-12-07 | 2024-09-18 | Vertex Pharmaceuticals Incorporated | Formes solides d'acide benzoïque 3-(6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) |
| CA2931134C (fr) | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Derives heteroaryles convenant comme modulateurs du cftr |
| SI2615085T1 (sl) | 2008-03-31 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Piridilni derivati kot cftr-modulatorji |
| WO2009131957A2 (fr) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Composés, compositions et traitements comprenant des dérivés d'oxydiazoles |
| US20090270398A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| WO2009131958A2 (fr) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Composés, compositions et procédés à base de dérivés de triazine |
| US8236838B2 (en) * | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| WO2009154739A2 (fr) * | 2008-06-17 | 2009-12-23 | Duke University | Modulateurs du récepteur smoothened |
| EP2341776A4 (fr) * | 2008-09-19 | 2012-05-30 | Inst Oneworld Health | Composés, compositions et procédés comprenant des dérivés d'imidazole et de triazole |
| JP2012504143A (ja) * | 2008-09-29 | 2012-02-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位 |
| BRPI0919930A2 (pt) * | 2008-10-23 | 2016-02-16 | Vertex Pharma | moduladores de regulador de condutância transmembrana de fibrose cística |
| EP3330255B1 (fr) | 2009-03-20 | 2020-12-09 | Vertex Pharmaceuticals Incorporated | Procédé de fabrication de modulateurs de régulateur de conductance transmembranaire de la fibrose kystique |
| US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
| US20120136003A1 (en) * | 2009-04-20 | 2012-05-31 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
| US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| HUE062892T2 (hu) | 2010-03-25 | 2023-12-28 | Vertex Pharma | (R)-1(2,2-difluorbenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluor-2-(1-hidroxi- 2-metilpropán-2-il)-1H-indol-5-il)ciklopropánkarboxamid elõállítása és köztitermékei |
| HRP20211752T1 (hr) | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
| MX2012011655A (es) | 2010-04-07 | 2012-11-23 | Vertex Pharma | Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico. |
| ES2858351T3 (es) | 2010-04-22 | 2021-09-30 | Vertex Pharma | Compuesto intermedio para proceso de producción de compuestos de cicloalquilcaraboxamido-indol |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| JP2013536231A (ja) | 2010-08-23 | 2013-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与 |
| CA2852991C (fr) | 2011-11-08 | 2019-12-31 | Vertex Pharmaceuticals Incorporated | Modulateurs de transporteurs de cassette de liaison a l'atp |
| SG10201606135TA (en) | 2012-01-25 | 2016-09-29 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| AU2013226076B2 (en) | 2012-02-27 | 2017-11-16 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP2872122A1 (fr) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques de (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide et son administration |
| SI2914248T2 (sl) | 2012-11-02 | 2023-12-29 | Vertex Pharmaceuticals Incorporated, | Farmacevtski sestavki za zdravljenje bolezni, pri katerih posreduje CFTR |
| US20160151335A1 (en) * | 2013-06-26 | 2016-06-02 | Proteostasis Therapeutics, Inc. | Methods of modulating cftr activity |
| US10231932B2 (en) | 2013-11-12 | 2019-03-19 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| AU2015229117A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
| EP3116501A1 (fr) | 2014-03-13 | 2017-01-18 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité du cftr |
| RU2744460C2 (ru) | 2014-04-15 | 2021-03-09 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости |
| CA2952862A1 (fr) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite du cftr |
| CN112250627B (zh) | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
| JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
| SG11201703963QA (en) | 2014-11-18 | 2017-06-29 | Vertex Pharma | Process of conducting high throughput testing high performance liquid chromatography |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| CA2971835A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derives de 3-heteroarylisoxazol-5-amide carboxylique utiles dans le traitement, entre autres, d'une fibrose kystique |
| US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| CA2971850A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derives d'amides 5-phenyl- ou 5-heteroarylthiazol-2-carboxyliques servant au traitement, entre autres, de la fibrose cystique |
| WO2017019589A1 (fr) | 2015-07-24 | 2017-02-02 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité du cftr |
| EP3359536B1 (fr) | 2015-10-06 | 2021-08-04 | Proteostasis Therapeutics, Inc. | Composés, compositions et méthodes permettant de moduler le cftr |
| EP3440057B1 (fr) | 2016-04-07 | 2021-09-22 | Proteostasis Therapeutics, Inc. | Analogues du ivacaftor conentant des atomes de silicium |
| WO2017223188A1 (fr) | 2016-06-21 | 2017-12-28 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité du cftr |
| RS62670B1 (sr) | 2016-09-30 | 2021-12-31 | Vertex Pharma | Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora |
| MX2019006637A (es) | 2016-12-09 | 2019-08-21 | Vertex Pharma | Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador. |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| CA3071278A1 (fr) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | Procedes de preparation de composes de pyrrolidine |
| CA3078893A1 (fr) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Formes cristallines et compositions de modulateurs de cftr |
| MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| US11066417B2 (en) | 2018-02-15 | 2021-07-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
| WO2019200246A1 (fr) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
| TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| MX2022001828A (es) | 2019-08-14 | 2022-06-08 | Vertex Pharma | Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr). |
| TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1318291A (en) | 1970-04-15 | 1973-05-23 | Shell Int Research | Carboxamide derivatives and fungicidal compositions containing them |
| JPS5041856A (fr) * | 1973-08-17 | 1975-04-16 | ||
| DE3932052A1 (de) * | 1989-09-26 | 1991-04-04 | Basf Ag | Oxazol- bzw. thiazolcarbonsaeureamide |
| US5244867A (en) * | 1989-09-26 | 1993-09-14 | Basf Aktiengesellschaft | Oxazole- and thiazolecarboxamides |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| JPH0441425A (ja) * | 1990-06-07 | 1992-02-12 | Tanabe Seiyaku Co Ltd | ５―リポキシゲナーゼ阻害剤 |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| IT1270882B (it) * | 1993-10-05 | 1997-05-13 | Isagro Srl | Oligopeptidi ad attivita' fungicida |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6096499A (en) * | 1996-03-22 | 2000-08-01 | Geron Corporation | Mammalian DNA primase screen and activity modulating agents |
| FR2751969B1 (fr) * | 1996-08-01 | 1998-12-04 | Centre Nat Rech Scient | Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant |
| JPH10338680A (ja) * | 1997-06-06 | 1998-12-22 | Takeda Chem Ind Ltd | チアゾール誘導体、その製造法および用途 |
| US6251629B1 (en) * | 1997-10-07 | 2001-06-26 | Smithkline Beecham Corporation | ABC transporter |
| DE69929996T2 (de) * | 1998-06-30 | 2006-11-16 | Takeda Pharmaceutical Co. Ltd. | Pharmazeutisches mittel zur behandlung von diabetes |
| CA2338697A1 (fr) * | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Composes et procedes |
| KR20010074779A (ko) * | 1998-07-28 | 2001-08-09 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | 치환된 아닐리드 화합물 및 제조방법 |
| US6096770A (en) * | 1998-08-03 | 2000-08-01 | American Home Products Corporation | Anthranilic acid analogs |
| JP4465779B2 (ja) * | 1999-02-10 | 2010-05-19 | 大正製薬株式会社 | 育毛剤 |
| BR0009539A (pt) * | 1999-04-02 | 2006-06-06 | Neurogen Corp | composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto |
| AUPQ309399A0 (en) * | 1999-09-28 | 1999-10-21 | Fujisawa Pharmaceutical Co., Ltd. | Benzothiazoline derivatives |
| AUPQ319899A0 (en) * | 1999-10-01 | 1999-10-28 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds |
| US6479231B1 (en) * | 1999-11-23 | 2002-11-12 | Gilead Sciences, Inc. | Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1 (hOAT1) |
| JP2001278872A (ja) * | 2000-03-27 | 2001-10-10 | Banyu Pharmaceut Co Ltd | 新規アミノチアゾール誘導体 |
| US20100074949A1 (en) * | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| AR034897A1 (es) * | 2001-08-07 | 2004-03-24 | Hoffmann La Roche | Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos |
| WO2003027100A1 (fr) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Inhibiteurs de lyase c17,20 a base de 3-pyridyle-pyrimidine substituee |
| JP4547912B2 (ja) * | 2002-03-05 | 2010-09-22 | 小野薬品工業株式会社 | ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| DE10250110A1 (de) | 2002-10-28 | 2004-05-13 | Bayer Cropscience Ag | Thiazol-(bi)cycloalkyl-carboxanilide |
| MXPA05008309A (es) * | 2003-02-10 | 2005-09-20 | Amgen Inc | Ligandos de receptor vaniloide y su uso en tratamientos. |
| US20050113423A1 (en) * | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
| US7109243B2 (en) * | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
| DE602004022819D1 (de) * | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| EP1675830A4 (fr) * | 2003-09-30 | 2008-08-20 | Scios Inc | Amides et sulfonamides heterocycliques |
| KR20060121909A (ko) * | 2003-10-08 | 2006-11-29 | 버텍스 파마슈티칼스 인코포레이티드 | 사이클로알킬 또는 피라닐 그룹을 포함하는 ａｔｐ-결합카세트 수송자의 조절자 |
| ES2328824T3 (es) * | 2003-11-14 | 2009-11-18 | Vertex Pharmaceuticals Incorporated | Tiazoles y oxazoles utiles como moduladores de transportadores de tipo casete de union a atp. |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2005075435A1 (fr) | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulateurs de transporteurs de type cassette de liaison a l'atp |
| ES2656017T3 (es) * | 2004-06-24 | 2018-02-22 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| US8242149B2 (en) * | 2005-03-11 | 2012-08-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| EP1891018B1 (fr) * | 2005-05-24 | 2011-11-16 | Vertex Pharmaceuticals, Inc. | Modulateurs des transporteurs de cassette de liaison a l'atp |
| KR20080053297A (ko) | 2005-08-11 | 2008-06-12 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유종 트랜스막 전도도 조정자의 조절자 |
| US8314256B2 (en) * | 2005-10-06 | 2012-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| EP1945632B1 (fr) * | 2005-11-08 | 2013-09-18 | Vertex Pharmaceuticals Incorporated | Modulateurs hétérocycliques de transporteurs à cassette liant l' atp |
| WO2007075901A2 (fr) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Promedicaments de modulateurs de transporteurs abc |
| CA2635214A1 (fr) * | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Composes utiles dans les bio-essais cftr et leurs procedes |
| US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2016065B1 (fr) * | 2005-12-28 | 2012-09-19 | Vertex Pharmaceuticals Incorporated | Dérivés de la 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide et composés similaires en tant que modulateurs des transporteurs de cassettes de liaison de l'atp pour le traitement de la fibrose cystique |
| DK3219705T3 (da) * | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
| US7645789B2 (en) * | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| CA2869945C (fr) * | 2006-04-07 | 2018-01-23 | Vertex Pharmaceuticals Incorporated | Modulateurs des transporteurs de cassettes de liaison de l'atp |
| ES2377840T3 (es) * | 2006-05-12 | 2012-04-02 | Vertex Pharmaceuticals, Inc. | Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida |
| US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| EP2170901B1 (fr) * | 2007-05-25 | 2015-07-01 | Vertex Pharmaceuticals Incorporated | Modulateurs de régulateur de conductance transmembranaire de fibrose cystique |
| CA2696298C (fr) * | 2007-08-24 | 2016-09-06 | Vertex Pharmaceuticals Incorporated | Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique |
| CA2699292A1 (fr) * | 2007-09-14 | 2009-03-26 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| NZ583878A (en) * | 2007-09-14 | 2012-10-26 | Vertex Pharma | Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR) |
| EP3012250B1 (fr) * | 2007-11-16 | 2017-11-08 | Vertex Pharmaceuticals Incorporated | Modulateurs d'isoquinoleine de transporteurs de cassette de liaison a l'atp |
| NZ612635A (en) * | 2007-12-07 | 2015-06-26 | Vertex Pharma | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| US20100036130A1 (en) * | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| JP2011506331A (ja) * | 2007-12-07 | 2011-03-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の処方物 |
| EP3683218B1 (fr) * | 2007-12-07 | 2024-09-18 | Vertex Pharmaceuticals Incorporated | Formes solides d'acide benzoïque 3-(6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) |
| AU2008335031B2 (en) * | 2007-12-13 | 2013-11-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA2931134C (fr) * | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Derives heteroaryles convenant comme modulateurs du cftr |
| SI2615085T1 (sl) * | 2008-03-31 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Piridilni derivati kot cftr-modulatorji |
| US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| JP2012504143A (ja) * | 2008-09-29 | 2012-02-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位 |
| NZ592687A (en) * | 2008-10-23 | 2013-04-26 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2011004374A (es) * | 2008-10-23 | 2011-05-23 | Vertex Pharma | Formas solidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-car boxamida. |
| BRPI0919930A2 (pt) * | 2008-10-23 | 2016-02-16 | Vertex Pharma | moduladores de regulador de condutância transmembrana de fibrose cística |
| US8367660B2 (en) * | 2008-12-30 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP3330255B1 (fr) * | 2009-03-20 | 2020-12-09 | Vertex Pharmaceuticals Incorporated | Procédé de fabrication de modulateurs de régulateur de conductance transmembranaire de la fibrose kystique |
| RU2543622C2 (ru) * | 2009-09-17 | 2015-03-10 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения азабициклических соединений |
| CA2777245A1 (fr) * | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions destinees au traitement de la mucoviscidose et d'autres maladies chroniques |
-
2004
- 2004-11-15 ES ES04811321T patent/ES2328824T3/es active Active
- 2004-11-15 WO PCT/US2004/038566 patent/WO2005049018A1/fr active Application Filing
- 2004-11-15 ZA ZA200604578A patent/ZA200604578B/en unknown
- 2004-11-15 EP EP04811321A patent/EP1682127B1/fr not_active Not-in-force
- 2004-11-15 CN CNA2004800394953A patent/CN1925854A/zh active Pending
- 2004-11-15 MX MXPA06005343A patent/MXPA06005343A/es unknown
- 2004-11-15 KR KR1020067011655A patent/KR20060121185A/ko not_active Application Discontinuation
- 2004-11-15 DE DE602004022319T patent/DE602004022319D1/de active Active
- 2004-11-15 EP EP09164393A patent/EP2140865A1/fr not_active Withdrawn
- 2004-11-15 CA CA002545719A patent/CA2545719A1/fr not_active Abandoned
- 2004-11-15 US US10/989,218 patent/US7407976B2/en active Active
- 2004-11-15 RU RU2006120549/04A patent/RU2006120549A/ru not_active Application Discontinuation
- 2004-11-15 AU AU2004290581A patent/AU2004290581B2/en not_active Ceased
- 2004-11-15 CN CN200910142522A patent/CN101675928A/zh active Pending
- 2004-11-15 AT AT04811321T patent/ATE437640T1/de not_active IP Right Cessation
- 2004-11-15 JP JP2006540025A patent/JP4869072B2/ja not_active Expired - Fee Related
- 2004-11-15 NZ NZ547220A patent/NZ547220A/en not_active IP Right Cessation
-
2006
- 2006-06-13 NO NO20062773A patent/NO20062773L/no not_active Application Discontinuation
- 2006-08-24 HK HK06109405.4A patent/HK1092353A1/xx not_active IP Right Cessation
-
2008
- 2008-07-31 US US12/183,580 patent/US7846951B2/en active Active
-
2010
- 2010-10-27 US US12/913,089 patent/US8232302B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ATE437640T1 (de) | 2009-08-15 |
| US20050130970A1 (en) | 2005-06-16 |
| EP1682127A1 (fr) | 2006-07-26 |
| DE602004022319D1 (de) | 2009-09-10 |
| US20090018140A1 (en) | 2009-01-15 |
| MXPA06005343A (es) | 2006-07-10 |
| ES2328824T3 (es) | 2009-11-18 |
| HK1092353A1 (en) | 2007-02-09 |
| AU2004290581B2 (en) | 2011-07-14 |
| CN1925854A (zh) | 2007-03-07 |
| KR20060121185A (ko) | 2006-11-28 |
| US7846951B2 (en) | 2010-12-07 |
| JP4869072B2 (ja) | 2012-02-01 |
| CA2545719A1 (fr) | 2005-06-02 |
| NO20062773L (no) | 2006-08-08 |
| NZ547220A (en) | 2009-12-24 |
| US7407976B2 (en) | 2008-08-05 |
| WO2005049018A1 (fr) | 2005-06-02 |
| US8232302B2 (en) | 2012-07-31 |
| AU2004290581A1 (en) | 2005-06-02 |
| EP1682127B1 (fr) | 2009-07-29 |
| JP2007511538A (ja) | 2007-05-10 |
| EP2140865A1 (fr) | 2010-01-06 |
| CN101675928A (zh) | 2010-03-24 |
| RU2006120549A (ru) | 2007-12-27 |
| US20110144123A1 (en) | 2011-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200604578B (en) | Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters | |
| US11291662B2 (en) | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | |
| US8609703B2 (en) | Modulators of ATP-binding cassette transporters | |
| US20100249180A1 (en) | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | |
| ES2647531T3 (es) | Derivados de heteroarilo como moduladores de CFTR | |
| ES2622154T3 (es) | Moduladores de transportadores de cassete de unión atp-binding | |
| CN101374849A (zh) | 作为abc转运蛋白调控剂的喹啉-4-酮衍生物 | |
| AU2008256717A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| AU2008335031A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| ZA200602755B (en) | Modulators of ATP-binding cassette transporters | |
| AU2020201314B2 (en) | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | |
| AU2018204203B2 (en) | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |